Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBunzl Regulatory News (BNZL)

Share Price Information for Bunzl (BNZL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3,106.00
Bid: 3,104.00
Ask: 3,108.00
Change: 20.00 (0.65%)
Spread: 4.00 (0.129%)
Open: 3,096.00
High: 3,114.00
Low: 3,090.00
Prev. Close: 3,086.00
BNZL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

14 Oct 2020 07:00

RNS Number : 9693B
Bunzl PLC
14 October 2020
 

14 October 2020

 

BUNZL Q3 TRADING STATEMENT

 

Bunzl plc, the specialist international distribution and services Group, today announces its trading statement for the period since 30 June 2020.

 

Bunzl's diversified and resilient business model has delivered strong overall growth over a challenging period, with Group revenue for the third quarter up 4.0% at actual exchange rates and 8.8% at constant exchange rates. Underlying revenue increased strongly by 8.0% at constant exchange rates reflecting the continued growth in the sale of Covid-19 related products, such as masks, sanitisers, gloves and disinfectants. Of the total growth at constant exchange rates, acquisitions contributed 4.0%, including the impact of MCR Safety which was completed at the beginning of September. The third quarter had fewer trading days than the comparable period in 2019 which reduced revenue growth at constant exchange rates by 3.2%.

 

Within the underlying revenue growth of 8.0%, sales of the top 8 Covid-19 related products, which are primarily own brand, contributed 17.5% of growth. This growth more than offset a 9.5% decline in revenue from other product sales. Larger orders of the top 8 Covid-19 related products, although lower than in the second quarter, were in line with expectations, with smaller orders also lower but remaining strong. The 9.5% decline in revenue from other product sales was less than the second quarter reflecting the easing of pandemic-related restrictions across the Company's markets.

 

The 2020 performance year to date has been driven by strong sales of Covid-19 related products, from a combination of smaller orders and the more exceptional larger orders. This has more than offset the impact of weak economic activity on the Group's business. Looking forward, the outlook remains uncertain, particularly considering current pandemic trends and the increasing restrictions which are now being reintroduced in some markets that may limit the continued underlying recovery. In addition, larger Covid-19 related orders are expected to be more limited. However, given the performance year to date and the impact of recently announced acquisitions, the Company currently expects revenue in the second half of 2020 to grow strongly at constant exchange rates and anticipates a slightly higher second half operating profit margin compared to the prior year.

 

Further to the announcement issued on 24 August 2020, the Company has recently completed the acquisition of Abco Kovex, a distributor of flexible packaging based in Ireland with revenue of €23 million. Growth through acquisitions continues to be an important part of the strategy of the Group and the acquisition pipeline remains promising with a number of discussions ongoing.

 

This announcement contains inside information.

 

 

Enquiries:

 

Bunzl plc

Frank van Zanten, Chief Executive Officer

Richard Howes, Chief Financial Officer

Tel: +44 (0)20 7725 5000

Tulchan

David Allchurch

Martin Robinson

Tel: +44 (0)20 7353 4200

 

Conference call:

 

There will be a live analyst and investor conference call and Q&A session from 08:00am (BST) today. To join the conference call refer to the dial-in details below (please allow time for registration).

 

· Dial-in number: +44 33 0606 1122

· Room number: 710652

 

The conference call replay will be available on demand later in the day via Bunzl's Investors section on the corporate website (https://www.bunzl.com/investors/presentations.aspx).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBUBDGLXBDGGX
Date   Source Headline
2nd May 20242:00 pmRNSDirector/PDMR Shareholding
2nd May 20248:00 amRNSAdditional Listing
1st May 20245:00 pmRNSDirector/PDMR Shareholding
1st May 202410:00 amRNSBlock listing Interim Review
1st May 20249:18 amRNSTotal Voting Rights
25th Apr 20244:45 pmRNSDirector/PDMR Shareholding
24th Apr 20242:51 pmRNSResult of AGM
24th Apr 20247:00 amRNSTrading Statement
22nd Apr 20244:36 pmRNSDirector/PDMR Shareholding
18th Apr 20248:00 amRNSAdditional Listing
11th Apr 20248:00 amRNSAdditional Listing
3rd Apr 20245:28 pmRNSDirector/PDMR Shareholding
3rd Apr 20249:09 amRNSDirector/PDMR Shareholding
2nd Apr 20241:50 pmRNSTotal Voting Rights
21st Mar 20248:00 amRNSAdditional Listing
15th Mar 20243:28 pmRNSAnnual Financial Report
7th Mar 20248:00 amRNSAdditional Listing
5th Mar 20245:05 pmRNSDirector/PDMR Shareholding
4th Mar 20243:03 pmRNSDirector/PDMR Shareholding
1st Mar 202411:35 amRNSTotal Voting Rights
28th Feb 20243:17 pmRNSDirector/PDMR Shareholding
27th Feb 20245:26 pmRNSDirector/PDMR Shareholding
26th Feb 202410:30 amRNSDividend Declaration
26th Feb 20247:00 amRNSFinal Results
26th Feb 20247:00 amRNSAcquisition
5th Feb 20242:20 pmRNSDirector/PDMR Shareholding
1st Feb 20245:08 pmRNSTotal Voting Rights
12th Jan 20244:54 pmRNSDirector/PDMR Shareholding
11th Jan 20243:50 pmRNSDirector/PDMR Shareholding
2nd Jan 202410:57 amRNSTotal Voting Rights
15th Dec 20235:10 pmRNSHolding(s) in Company
14th Dec 20237:00 amRNSTrading Statement
8th Dec 20235:32 pmRNSDirector/PDMR Shareholding
1st Dec 202311:32 amRNSTotal Voting Rights
20th Nov 20236:30 pmRNSPublication of Admission Particulars
3rd Nov 20239:30 amRNSDirector Declaration
2nd Nov 20232:29 pmRNSDirector/PDMR Shareholding
1st Nov 202311:24 amRNSTotal Voting Rights
1st Nov 20239:00 amRNSBlock listing Interim Review
24th Oct 20237:00 amRNSTrading Statement
6th Oct 20235:08 pmRNSDirector/PDMR Shareholding
4th Oct 20231:40 pmRNSDirector/PDMR Shareholding
2nd Oct 20231:34 pmRNSTotal Voting Rights
2nd Oct 20231:33 pmRNSDirector/PDMR Shareholding
26th Sep 20232:10 pmRNSDirector/PDMR Shareholding
1st Sep 20232:30 pmRNSTotal Voting Rights
31st Aug 202310:30 amRNSDirector/PDMR Shareholding
29th Aug 202310:00 amRNSDividend Declaration
29th Aug 20237:00 amRNSHalf-year Report
29th Aug 20237:00 amRNSAcquisition

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.